Desai Sethi Urology Institute, University of Miami, Miami, FL 33136, United States.
Sex Med Rev. 2023 Sep 27;11(4):369-374. doi: 10.1093/sxmrev/qead032.
Erectile dysfunction (ED) is the inability to achieve or maintain erection for satisfactory sexual performance. ED drastically reduces the quality of life for men and their partners and is commonly linked to comorbid conditions such as diabetes and cardiovascular disease. As a result, clinicians and researchers are working to improve treatments for ED. Current guideline-approved ED treatments include oral phosphodiesterase type 5 inhibitors, intraurethral alprostadil, penile intracavernosal injections, and penile prosthesis surgery. Today, there is increasing interest in restorative therapies such as intracavernosal platelet-rich plasma (PRP) for the management of ED.
This narrative review describes the current trials investigating intracavernosal PRP for ED and proposes future directions to increase the strength of evidence to support use of PRP in this population.
A comprehensive literature search of PubMed, Science Direct, and Scopus was performed to identify all randomized clinical trials using PRP for the treatment of ED.
We identified 4 randomized clinical trials investigating the safety and efficacy of PRP for ED. We found significant heterogeneity among study protocols, including collection of PRP, dosing of PRP, and follow-up.
While intracavernosal PRP is considered safe, its efficacy for the management of ED remains unknown due to variability among clinical trials.
勃起功能障碍(ED)是指无法获得或维持满意的性行为所需的勃起。ED 极大地降低了男性及其伴侣的生活质量,并且通常与糖尿病和心血管疾病等合并症相关。因此,临床医生和研究人员正在努力改善 ED 的治疗方法。目前指南批准的 ED 治疗方法包括口服磷酸二酯酶 5 抑制剂、尿道内前列地尔、阴茎海绵体内注射和阴茎假体手术。如今,人们对恢复性治疗(如阴茎海绵体内富含血小板的血浆(PRP))治疗 ED 越来越感兴趣。
本叙述性综述描述了目前正在进行的关于 PRP 治疗 ED 的临床试验,并提出了未来的方向,以增强支持在该人群中使用 PRP 的证据强度。
对 PubMed、Science Direct 和 Scopus 进行了全面的文献检索,以确定所有使用 PRP 治疗 ED 的随机临床试验。
我们确定了 4 项研究 PRP 治疗 ED 的安全性和有效性的随机临床试验。我们发现研究方案存在显著的异质性,包括 PRP 的采集、PRP 的剂量和随访。
尽管阴茎海绵体内 PRP 被认为是安全的,但由于临床试验之间的差异,其治疗 ED 的疗效仍不清楚。